TY - JOUR AU - Davis, C. J. AU - Mostofi, F. K. AU - Sesterhenn, I. A. PY - 1995 DA - 1995// TI - Renal medullary carcinoma. The seventh sickle cell nephropathy JO - Am J Surg Pathol VL - 19 UR - https://doi.org/10.1097/00000478-199501000-00001 DO - 10.1097/00000478-199501000-00001 ID - Davis1995 ER - TY - JOUR AU - Alvarez, O. AU - Rodriguez, M. M. AU - Jordan, L. AU - Sarnaik, S. PY - 2015 DA - 2015// TI - Renal medullary carcinoma and sickle cell trait: a systematic review JO - Pediatr Blood Cancer VL - 62 UR - https://doi.org/10.1002/pbc.25592 DO - 10.1002/pbc.25592 ID - Alvarez2015 ER - TY - JOUR AU - Figenshau, R. S. AU - Basler, J. W. AU - Ritter, J. H. AU - Siegel, C. L. AU - Simon, J. A. PY - 1998 DA - 1998// TI - Renal medullary carcinoma JO - J Urol VL - 159 UR - https://doi.org/10.1016/S0022-5347(01)63707-8 DO - 10.1016/S0022-5347(01)63707-8 ID - Figenshau1998 ER - TY - STD TI - Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, et al. Management and Outcomes of Patients with Renal Medullary Carcinoma: A Multi-Center Collaborative Study. BJU Int. 2016. ID - ref4 ER - TY - JOUR AU - Cheng, J. X. AU - Tretiakova, M. AU - Gong, C. AU - Mandal, S. AU - Krausz, T. PY - 2008 DA - 2008// TI - Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior JO - Mod Pathol VL - 21 UR - https://doi.org/10.1038/modpathol.2008.44 DO - 10.1038/modpathol.2008.44 ID - Cheng2008 ER - TY - JOUR AU - Calderaro, J. AU - Moroch, J. AU - Pierron, G. AU - Pedeutour, F. AU - Grison, C. PY - 2012 DA - 2012// TI - SMARCB1/INI1 inactivation in renal medullary carcinoma JO - Histopathology VL - 61 UR - https://doi.org/10.1111/j.1365-2559.2012.04228.x DO - 10.1111/j.1365-2559.2012.04228.x ID - Calderaro2012 ER - TY - JOUR AU - Calderaro, J. AU - Masliah-Planchon, J. AU - Richer, W. AU - Maillot, L. AU - Maille, P. PY - 2016 DA - 2016// TI - Balanced translocations disrupting SMARCB1 Are hallmark recurrent genetic alterations in renal medullary carcinomas JO - Eur Urol VL - 69 UR - https://doi.org/10.1016/j.eururo.2015.09.027 DO - 10.1016/j.eururo.2015.09.027 ID - Calderaro2016 ER - TY - JOUR AU - Ho, T. H. AU - Swensen, J. AU - Ghazalpour, A. AU - Hes, O. AU - Stanton, M. L. AU - Josehi, M. PY - 2016 DA - 2016// TI - Comprehensive profiling of renal medullary and collecting duct carcinomas JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.61.5385 DO - 10.1200/JCO.2015.61.5385 ID - Ho2016 ER - TY - JOUR AU - Iacovelli, R. AU - Modica, D. AU - Palazzo, A. AU - Trenta, P. AU - Piesco, G. PY - 2015 DA - 2015// TI - Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature JO - Can Urol Assoc J VL - 9 UR - https://doi.org/10.5489/cuaj.2373 DO - 10.5489/cuaj.2373 ID - Iacovelli2015 ER - TY - JOUR AU - Tannir, N. M. AU - Plimack, E. AU - Ng, C. AU - Tamboli, P. AU - Bekele, N. B. PY - 2012 DA - 2012// TI - A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma JO - Eur Urol VL - 62 UR - https://doi.org/10.1016/j.eururo.2012.06.043 DO - 10.1016/j.eururo.2012.06.043 ID - Tannir2012 ER - TY - JOUR AU - Lipkin, J. S. AU - Rizvi, S. M. AU - Gatalica, Z. AU - Sarwani, N. E. AU - Holder, S. L. PY - 2015 DA - 2015// TI - Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression JO - Cancer Biol Ther VL - 16 UR - https://doi.org/10.4161/15384047.2014.972843 DO - 10.4161/15384047.2014.972843 ID - Lipkin2015 ER - TY - JOUR AU - Rathmell, W. K. AU - Monk, J. P. PY - 2008 DA - 2008// TI - High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review JO - Urology VL - 72 UR - https://doi.org/10.1016/j.urology.2008.05.009 DO - 10.1016/j.urology.2008.05.009 ID - Rathmell2008 ER - TY - JOUR AU - Strouse, J. J. AU - Spevak, M. AU - Mack, A. K. AU - Arceci, R. J. AU - Small, D. PY - 2005 DA - 2005// TI - Significant responses to platinum-based chemotherapy in renal medullary carcinoma JO - Pediatr Blood Cancer VL - 44 UR - https://doi.org/10.1002/pbc.20292 DO - 10.1002/pbc.20292 ID - Strouse2005 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. PY - 2015 DA - 2015// TI - Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Rosenberg, J. E. AU - Hoffman-Censits, J. AU - Powles, T. AU - Heijden, M. S. AU - Balar, A. V. PY - 2016 DA - 2016// TI - Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00561-4 DO - 10.1016/S0140-6736(16)00561-4 ID - Rosenberg2016 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. AU - Song, C. AU - Moreno, B. H. PY - 2016 DA - 2016// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.065 DO - 10.1016/j.cell.2016.02.065 ID - Hugo2016 ER - TY - JOUR AU - Heninger, E. AU - Krueger, T. E. AU - Lang, J. M. PY - 2015 DA - 2015// TI - Augmenting antitumor immune responses with epigenetic modifying agents JO - Front Immunol VL - 6 ID - Heninger2015 ER - TY - JOUR AU - Yang, H. AU - Bueso-Ramos, C. AU - DiNardo, C. AU - Estecio, M. R. AU - Davanlou, M. PY - 2014 DA - 2014// TI - Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.355 DO - 10.1038/leu.2013.355 ID - Yang2014 ER - TY - JOUR AU - Toor, A. A. AU - Payne, K. K. AU - Chung, H. M. AU - Sabo, R. T. AU - Hazlett, A. F. PY - 2012 DA - 2012// TI - Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity JO - Br J Haematol VL - 158 UR - https://doi.org/10.1111/j.1365-2141.2012.09225.x DO - 10.1111/j.1365-2141.2012.09225.x ID - Toor2012 ER - TY - JOUR AU - Kovac, M. AU - Navas, C. AU - Horswell, S. AU - Salm, M. AU - Bardella, C. PY - 2015 DA - 2015// TI - Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms7336 DO - 10.1038/ncomms7336 ID - Kovac2015 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Daud, A. I. AU - Loo, K. AU - Pauli, M. L. AU - Sanchez-Rodriguez, R. AU - Sandoval, P. M. PY - 2016 DA - 2016// TI - Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI87324 DO - 10.1172/JCI87324 ID - Daud2016 ER -